Piper Jaffray Cuts PT on Inovio Pharma (INO) to $13 Following FDA Clinical Hold; Affirms at 'Overweight'

October 24, 2016 3:00 PM EDT
Get Alerts INO Hot Sheet
Price: $7.09 +0.14%

Rating Summary:
    8 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 26 | New: 28
Trade INO Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Piper Jaffray cut its price target on Overweight-rated Inovio Pharma (Nasdaq: INO) from $31 to $13 after the company announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its proposed phase III clinical program for VGX-3100.

The firm commented on Monday: We believe that Inovio may be able to submit this information as soon as YE16, pointing to a 2017, and potentially 1H17, trial start. We are taking our PT to $13 as we think today’s news raises clinical risk for VGX-3100 in the near-term and pushes out already extended timelines to value creation from clinical data and approval for this program. That said, we are believe this device-specific request can be resolved reasonably soon and that it is not, ultimately, a program-stopper for VGX-3100 or Inovio’s other clinical-stage programs. Therefore in advance of anticipated updates regarding the clinical hold for Inovio’s lead program, as well as progress from the earlier-stage pipeline, we reiterate [Overweight].

For an analyst ratings summary and ratings history on Inovio Pharmaceuticals click here. For more ratings news on Inovio Pharmaceuticals click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Piper Jaffray

Add Your Comment